Connolly Mary, Mullan Ronan H, McCormick Jennifer, Matthews Clare, Sullivan Owen, Kennedy Aisling, FitzGerald Oliver, Poole A Robin, Bresnihan Barry, Veale Douglas J, Fearon Ursula
St. Vincent's University Hospital, Dublin Academic Medical Centre, The Conway Institute of Biomolecular and Biomedical Research, Dublin, Ireland.
Arthritis Rheum. 2012 Apr;64(4):1035-45. doi: 10.1002/art.33455. Epub 2011 Nov 10.
To investigate the relationship between acute-phase serum amyloid A (A-SAA) and joint destruction in inflammatory arthritis.
Serum A-SAA and C-reactive protein (CRP) levels, the erythrocyte sedimentation rate (ESR), and levels of matrix metalloproteinase 1 (MMP-1), MMP-2, MMP-3, MMP-9, MMP-13, tissue inhibitor of metalloproteinases 1 (TIMP-1), vascular endothelial growth factor (VEGF), and type I and type II collagen-generated biomarkers C2C and C1,2C were measured at 0-3 months in patients with inflammatory arthritis commencing anti-tumor necrosis factor α (anti-TNFα) therapy and were correlated with 1-year radiographic progression. The effects of A-SAA on MMP/TIMP expression on RA fibroblast-like synoviocytes (FLS), primary human chondrocytes, and RA/psoriatic arthritis synovial explant cultures were assessed using real-time polymerase chain reaction, enzyme-linked immunosorbent assay, antibody protein arrays, and gelatin zymography.
Serum A-SAA levels were significantly (P < 0.05) correlated with MMP-3, the MMP-3:TIMP-1 ratio, C1,2C, C2C, and VEGF. The baseline A-SAA level but not the ESR or the CRP level correlated with the 28-joint swollen joint count and was independently associated with 1-year radiographic progression (P = 0.038). A-SAA increased MMP-1, MMP-3, MMP-13, and MMP/TIMP expression in RA FLS and synovial explants (P < 0.05). In chondrocytes, A-SAA induced MMP-1, MMP-3, and MMP-13 messenger RNA and protein expression (all P < 0.01), resulting in a significant shift in MMP:TIMP ratios (P < 0.05). Gelatin zymography revealed that A-SAA induced MMP-2 and MMP-9 activity. Blockade of the A-SAA receptor SR-B1 (A-SAA receptor scavenger receptor-class B type 1) inhibited MMP-3, MMP-2, and MMP-9 expression in synovial explant cultures ex vivo. Importantly, we demonstrated that A-SAA has the ability to induce TNFα expression in RA synovial explant cultures (P < 0.05).
A-SAA may be involved in joint destruction though MMP induction and collagen cleavage in vivo. The ability of A-SAA to regulate TNFα suggests that A-SAA signaling pathways may provide new therapeutic strategies for the treatment of inflammatory arthritis.
探讨急性期血清淀粉样蛋白A(A-SAA)与炎性关节炎关节破坏之间的关系。
在开始抗肿瘤坏死因子α(抗TNFα)治疗的炎性关节炎患者中,于0至3个月时测定血清A-SAA和C反应蛋白(CRP)水平、红细胞沉降率(ESR)以及基质金属蛋白酶1(MMP-1)、MMP-2、MMP-3、MMP-9、MMP-13、金属蛋白酶组织抑制剂1(TIMP-1)、血管内皮生长因子(VEGF)水平,以及I型和II型胶原生成的生物标志物C2C和C1,2C,并将其与1年的放射学进展相关联。使用实时聚合酶链反应、酶联免疫吸附测定、抗体蛋白阵列和明胶酶谱法评估A-SAA对类风湿关节炎成纤维样滑膜细胞(FLS)、原代人软骨细胞以及类风湿关节炎/银屑病关节炎滑膜外植体培养物中MMP/TIMP表达的影响。
血清A-SAA水平与MMP-3、MMP-3:TIMP-1比值、C1,2C、C2C和VEGF显著相关(P < 0.05)。基线A-SAA水平而非ESR或CRP水平与28个关节的肿胀关节计数相关,并且与1年的放射学进展独立相关(P = 0.038)。A-SAA增加了类风湿关节炎FLS和滑膜外植体中MMP-1、MMP-3、MMP-13以及MMP/TIMP的表达(P < 0.05)。在软骨细胞中,A-SAA诱导了MMP-1、MMP-3和MMP-13信使核糖核酸及蛋白表达(均P < 0.01),导致MMP:TIMP比值发生显著变化(P < 0.05)。明胶酶谱法显示A-SAA诱导了MMP-2和MMP-9活性。阻断A-SAA受体SR-B1(A-SAA受体清道夫受体B类I型)可在体外抑制滑膜外植体培养物中MMP-3、MMP-2和MMP-9的表达。重要的是,我们证明A-SAA有能力在类风湿关节炎滑膜外植体培养物中诱导TNFα表达(P < 0.05)。
A-SAA可能通过体内诱导MMP和裂解胶原参与关节破坏。A-SAA调节TNFα的能力表明A-SAA信号通路可能为炎性关节炎的治疗提供新的治疗策略。